Project Grant R21AI190247
Award Date
4/24/25
Completion Date
3/31/27
Dollars Obligated
$233K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This $371,150 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to characterize a novel Brucella small RNA, called BSR7, that is critical for the cell envelope integrity of this pathogenic bacteria. The research aims to determine if deletion of BSR7 will attenuate Brucella abortus in both macrophage and animal infection models. Additionally, the project will...
This Project Grant award of $1,900,294 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to advance the molecular-level understanding of a signal transduction system that influences the ability of the bacterium Brucella abortus to survive stress conditions and colonize mammalian hosts. The key objectives are to: 1) define the mechanism of stress signal detection by the multi-kinase...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $790,012 to the University of Vermont & State Agricultural College to conduct research on the structure and functions of a bacterial type IV effector complex. The key objectives are to: 1) Determine the structure and assembly of a multi-effector protein complex composed of three bacterial proteins...
This federal Project Grant award in the amount of $520,809, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at understanding the role of TAM receptors in modulating the humoral immune response against parasitic infections, particularly malaria. The overarching goal of this 5-year research program is to identify molecular and cellular immune mechanisms that contribute to...
This $147,712 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research will fund research investigating how the Mycobacterium tuberculosis (MTB) protein Rv1075c interacts with the host's histone methyltransferase complexes to influence gene expression and promote MTB infection. The key objectives are to define how histone methylation changes at innate immune genes during MTB infection, and to examine how...
This $104,552 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at The Washington University in St. Louis to investigate how the Mycobacterium tuberculosis (MTB) pathogen promotes its survival within neutrophils, the most abundant immune cells infected during tuberculosis (TB). The research aims to elucidate the mechanisms by which the MTB type VII secretion...
The federal Project Grant award of $451,292.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to uncover neuronal mechanisms regulating metabolic adaptations to bacterial infections, with a focus on the brain-liver axis. The primary goals are to: 1) identify neurocircuits in the hypothalamus that monitor circulating lipoproteins and trigger counterregulatory responses during infections, and 2)...
This $130,776 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Lake Forest College. The grant will fund research to characterize the role of the mycobacterial BrkB ortholog, a potential drug target, in the pathogenesis of tuberculosis (TB). The project aims to identify BrkB's biochemical function, its mechanism for requiring extracellular growth, and its impact on...
This federal Project Grant award, totaling $3,559,162.00, was provided by the National Institutes of Health (NIH) through the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to investigate modulating indoleamines to optimize immunity in the setting of Mycobacterium tuberculosis (MTB)/HIV co-infection. The research will utilize macaque models to study the role of the indoleamine 2,3-dioxygenase (IDO) pathway in inhibiting effective immunity to TB and orchestrating...
This $899,894 Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate early immune cell interactions and signaling pathways that contribute to tuberculosis (TB) disease outcomes during HIV/TB co-infection. The primary awardee, The Washington University in St. Louis, will lead studies to define the roles of type I interferon (IFN) signaling and...